Drugs / EN001
EN001
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05333406 | Feb → Dec 2022 | Charcot-Marie-Tooth disease | ENCell | Completed | No outcome recorded |
| Phase 1 | NCT05338099 | Jan → Dec 2022 | Duchenne muscular dystrophy | ENCell | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06218134 | May → Oct 2024 | Charcot-Marie-Tooth disease type 1 | Samsung Medical Center | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1/2 | NCT06328712 Comparator | May 2024 → Dec 2026 expected | Charcot-Marie-Tooth disease type 1A | ENCell | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06328725 Comparator | Mar 2024 → Nov 2025 | Duchenne muscular dystrophy | ENCell | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EN001 | “human Wharton's jelly-derived mesenchymal stem cells(product name: EN001)” NCT06218134 ↗ |
| Known as | EN001 (Allogeneic early-passage Wharton's jelly-derived mesenchymal stem cells) | “EN001 (Allogeneic early-passage Wharton's jelly-derived mesenchymal stem cells)” NCT05338099 ↗ |
| Modality | Cell therapy | “EN001 (allogeneic umbilical cord-derived mesenchymal stem cells)” NCT05333406 ↗ |
| Route | Intravenous | “EN001 intravenously (IV)” NCT05333406 ↗ |